Abstract:Background: Type I IFN-based therapies against solid malignancies have yielded only limited success. How 1FN affects tumor-associated macrophage (TAM) compartment to impact the therapeutic outcomes are not well understood. Methods: The effect of an IFN-inclucer poly(1:C) on tumor-infiltrating monocytes and TAMs were analyzed using a transplantable mouse tumor model (LLC). in vitro culture systems were utilized to study the direct actions by poly(I:C)-IFN on differentiating monocytes. Results: We found that poly(LC)-induced IFN targets Ly6C monocytes and impedes their transition into TAMs. Such an effect involves miR-155-mediated suppression of M-CSF receptor expression, contributing to restricting tumor growth. Remarkably, further analyses of gene expression profile of IFN-treated differentiating monocytes reveal a strong induction of Arg I (encoding arginase-1) in addition to other classical IFN targets. Mechanistically, the unexpected Argl arm of IFN action is mediated by a prolonged STAT3 signaling in monocytes, in conjunction with elevated macrophage colony-stimulating factor (M-CSF) signaling. Functionally, induction of ARG1 limited the therapeutic effect of IFNI, as inhibition of arginase activity could strongly synergize with poly(LC) to enhance CD8 T cell responses to thwart tumor growth in mice. Conclusions: Taken together, we have uncovered two functionally opposing actions by 1FN on the TAM compartment. Our work provides significant new insights on IFN-mediated immunoregulation that may have implications in cancer therapies. (C) 2018 The Authors. Published by Elsevier B.V.

Concomitant Type I IFN and M-CSF Signaling Reprograms Monocyte Differentiation and Drives Pro-Tumoral Arginase Production